<DOC>
	<DOCNO>NCT01496742</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety RO5490258 ( MetMab ) combination either two backbone chemotherapy regimens first-line set patient incurable Stage IIIB IV non-squamous non-small cell lung cancer . In Cohort 1 , patient randomize receive 4 cycle bevacizumab ( Avastin ) 15 mg/kg iv , paclitaxel 200 mg/m2 iv , platinum ( cisplatin/carboplatin ) iv plus either MetMab 15 mg/kg iv placebo Day 1 21-day cycle . In Cohort 2 , patient randomize receive pemetrexed 500 mg/m2 iv , platinum ( cisplatin/carboplatin ) iv plus either MetMAb 15 mg/m2 iv placebo Day 1 21-day cycle . Patients progress 4 cycle offer maintenance therapy assign treatment bevacizumab plus either MetMAb placebo ( Cohort 1 ) pemetrexed plus either MetMAb placebo ( Cohort 2 ) . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Onartuzumab ( MetMAb ) Combination With Bevacizumab ( Avastin ) Plus Platinum And Paclitaxel With Pemetrexed Plus Platinum Patients With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm Stage IIIB Stage IV nonsquamous nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 For patient receive prior adjuvant chemotherapy chemoradiotherapy : treatmentfree interval least 12 month since last chemotherapy chemoradiotherapy cycle Adequate tissue central immunohistochemical ( IHC ) assay Met receptor , epidermal growth factor receptor ( EGFR ) test EGFR status unknown Radiographic evidence disease Prior systemic treatment Stage IIIB IV nonsquamous NSCLC Evidence mix NSCLC predominance squamous cell type Prior exposure experimental treatment target either hepatocyte growth factor ( HGF ) Met pathway Patients tumor confirm EGFRactivating mutation suitable antiEGFR therapy ( e.g . gefitinib erlotinib ) , determine investigator , unless treatment unavailable refuse patient Known central nervous system ( CNS ) disease , stable , treated brain metastasis History another malignancy previous 3 year , except history situ cancer treat surgically curative intent , localized prostate cancer treat surgically curative intent , basal squamous cell skin cancer Uncontrolled diabetes Pregnant lactate woman Impaired bone marrow , liver renal function ( define protocol ) Significant history cardiovascular disease Positive HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>